.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
US Army
Mallinckrodt
Fuji
Baxter
Julphar
Chinese Patent Office
Dow
Deloitte
Cipla

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021753

« Back to Dashboard

NDA 021753 describes DIFFERIN, which is a drug marketed by Galderma Labs Lp and is included in five NDAs. It is available from eight suppliers. There are nine patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DIFFERIN profile page.

The generic ingredient in DIFFERIN is adapalene. There are eleven drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the adapalene profile page.

Summary for 021753

Tradename:1
Applicant:1
Ingredient:1
Patents:6
Therapeutic Class:Dermatological Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 021753

Ingredient-typeRetinoids

Medical Subject Heading (MeSH) Categories for 021753

Suppliers and Packaging for NDA: 021753

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DIFFERIN adapalene GEL;TOPICAL 021753 NDA Galderma Laboratories, L.P. 0299-5918 0299-5918-45 1 TUBE in 1 CARTON (0299-5918-45) > 45 g in 1 TUBE
DIFFERIN adapalene GEL;TOPICAL 021753 NDA Galderma Laboratories, L.P. 0299-5918 0299-5918-15 1 TUBE in 1 CARTON (0299-5918-15) > 15 g in 1 TUBE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:GEL;TOPICALStrength0.3%
Approval Date:Jun 19, 2007TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Feb 23, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TOPICAL TREATMENT OF ACNE VULGARIS
Patent:► SubscribePatent Expiration:Aug 29, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Mar 12, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ACNE

Expired Orange Book Patents for NDA: 021753

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Galderma Labs LpDIFFERINadapaleneGEL;TOPICAL021753-001Jun 19, 2007► Subscribe► Subscribe
Galderma Labs LpDIFFERINadapaleneGEL;TOPICAL021753-001Jun 19, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Deloitte
QuintilesIMS
Cantor Fitzgerald
Covington
US Army
Moodys
Mallinckrodt
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot